Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Finding MYCure

  • Beaulieu, Marie-Eve
  • Soucek, Laura
MYC; Peptide therapeutic; Mini-protein, MYC; Péptido terapéutico; Mini-proteína, MYC; Pèptid terapèutic; Mini-proteïna, Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine "Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy", we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein., This work was supported by the European Research Council [617473];Instituto de Salud Carlos III [PI13/01705]; BBVA Foundation [67_2015];Worlwide Cancer Research [13-1182].
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation

  • Fiorentino, Francesco Paolo
  • Tokgün, Elvan
  • Solé-Sánchez, Sònia
  • Giampaolo, Sabrina
  • Tokgün, Onur
  • Jauset González, Toni
  • Kohno, Takashi|||0000-0002-5371-706X
  • Perucho, Manuel|||0000-0002-2169-2662
  • Soucek, Laura|||0000-0002-4750-7971
  • Yokota, Jun|||0000-0001-6010-6294
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer with high mortality. One of the MYC family genes, MYC, MYCL or MYCN, is amplified in ~20% of the SCLCs; therefore, MYC proteins are potential therapeutic targets in SCLC patients. We investigated the therapeutic impact of Omomyc, a MYC dominant negative, in a panel of SCLC cell lines. Strikingly, Omomyc suppressed the growth of all tested cell lines by inducing cell cycle arrest and/or apoptosis. Induction of G1 arrest by Omomyc was found to be dependent on the activation of CDKN1A, in part, through the TP73 pathway. Our results strongly indicate that SCLC cells carrying amplification of MYC, MYCL or MYCN are addicted to MYC function, suggesting that MYC targeting would be an efficient therapeutic option for SCLC patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Strategies to Inhibit Myc and Their Clinical Applicability

  • Whitfield, Jonathan R.|||0000-0002-4925-7283
  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Soucek, Laura|||0000-0002-4750-7971
Myc is an oncogene deregulated in most-perhaps all-human cancers. Each Myc family member, c-, L-, and N-Myc, has been connected to tumor progression and maintenance. Myc is recognized as a "most wanted" target for cancer therapy, but has for many years been considered undruggable, mainly due to its nuclear localization, lack of a defined ligand binding site, and physiological function essential to the maintenance of normal tissues. The challenge of identifying a pharmacophore capable of overcoming these hurdles is reflected in the current absence of a clinically-viable Myc inhibitor. The first attempts to inhibit Myc used antisense technology some three decades ago, followed by small molecule inhibitors discovered through "classical" compound library screens. Notable breakthroughs proving the feasibility of systemic Myc inhibition were made with the Myc dominant negative mutant Omomyc, showing both the great promise in targeting this infamous oncogene for cancer treatment as well as allaying fears about the deleterious side effects that Myc inhibition might have on normal proliferating tissues. During this time many other strategies have appeared in an attempt to drug the undruggable, including direct and indirect targeting, knockdown, protein/protein and DNA interaction inhibitors, and translation and expression regulation. The inhibitors range from traditional small molecules to natural chemicals, to RNA and antisense, to peptides and miniproteins. Here, we briefly describe the many approaches taken so far, with a particular focus on their potential clinical applicability.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC

  • Jauset González, Toni
  • Massó Vallés, Daniel|||0000-0003-4231-0456
  • Martínez Martín, Sandra
  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • Fiorentino, Francesco Paolo
  • Yokota, Jun|||0000-0001-6010-6294
  • Haendler, Bernard
  • Siegel, Stephan
  • Whitfield, Jonathan R.|||0000-0002-4925-7283
  • Soucek, Laura|||0000-0002-4750-7971
Effectively treating KRAS-driven tumors remains an unsolved challenge. The inhibition of downstream signaling effectors is a way of overcoming the issue of direct targeting of mutant KRAS, which has shown limited efficacy so far. Bromodomain and Extra-Terminal (BET) protein inhibition has displayed anti-tumor activity in a wide range of cancers, including KRAS-driven malignancies. Here, we preclinically evaluate the effect of BET inhibition making use of a new BET inhibitor, BAY 1238097, against Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC) models harboring RAS mutations both in vivo and in vitro. Our results demonstrate that BET inhibition displays significant therapeutic impact in genetic mouse models of KRAS-driven PDAC and NSCLC, reducing both tumor area and tumor grade. The same approach also causes a significant reduction in cell number of a panel of RAS-mutated human cancer cell lines (8 PDAC and 6 NSCLC). In this context, we demonstrate that while BET inhibition by BAY 1238097 decreases MYC expression in some cell lines, at least in PDAC cells its anti-tumorigenic effect is independent of MYC regulation. Together, these studies reinforce the use of BET inhibition and prompt the optimization of more efficient and less toxic BET inhibitors for the treatment of KRAS-driven malignancies, which are in urgent therapeutic need.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Finding MYCure

  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Soucek, Laura|||0000-0002-4750-7971
Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine "Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy", we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Finding MYCure

  • Beaulieu, Marie-Eve
  • Soucek, Laura
MYC; Peptide therapeutic; Mini-protein, MYC; Péptido terapéutico; Mini-proteína, MYC; Pèptid terapèutic; Mini-proteïna, Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine "Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy", we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein., This work was supported by the European Research Council [617473];Instituto de Salud Carlos III [PI13/01705]; BBVA Foundation [67_2015];Worlwide Cancer Research [13-1182].